Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Max-interacting protein 1 (MXI1) is a transcriptional repressor that belongs to the basic helix-loop-helix leucine zipper (bHLH-Zip) family of transcription factors[1][8]. MXI1 binds to the MAX protein to form heterodimers, creating a complex that recognizes the same DNA consensus sequences targeted by the MYC-MAX complex[1][2][8]. By competing for MAX and DNA binding sites, MXI1 antagonizes the oncogenic activity of MYC, thereby acting as a potential tumor suppressor[2][5][8]. MXI1 is widely expressed in human tissues and has been particularly implicated in prostate cancer and neurofibrosarcoma, often showing defects or mutations in these disease states[3][5][7]. The protein does not currently have any approved drugs that directly target it[5][7][8]. Its principal function is transcriptional repression and inhibition of MYC-driven gene expression, which regulates cell proliferation and differentiation[1][2][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Max-interacting protein 1 (MXI1).